Carna Bioscience To Out-License Kinase Inhibitor With ¥100 Million In Mind
This article was originally published in PharmAsia News
Tokyo based Carna Biosciences Inc. is readying its kinase inhibitor for an out-licensing deal in 2012, disclosed company President Koichiro Yoshino during a Feb. 13 earnings call.
You may also be interested in...
During a recent press briefing, health officials in China disclosed the country is poised to reach an annual production capacity of 610 million doses for coronavirus vaccines. But they said prices must be based on manufacturing costs and not driven by supply and demand.
Biocon Biologics upbeat on Lantus follow-on’s long revenue stream and prospects for interchangeability, while operational challenges resulted in some supply constraints during the fiscal second quarter.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.